In a recent webcast, Dr. Ronald Korn, Founder and CMO at Imaging Endpoints and Kelie Williams Luby, VP Clinical Trials Software at Mint Medical, presented an integrated, comprehensive analysis using the mint Lesion™ platform for a seamless evaluation of COVID-19 patients and trials.
Together they highlighted the need for expert image analysis and the urgent need for organized data collection, encompassing the multi-dimensional data of imaging, laboratory, clinical, and demographics for COVID-19.
While imaging should not be used as a screening tool for unselected populations, it supports a comprehensive approach which can be applied in both clinical care and clinical trials. The mint Lesion™ platform integrates this multi-dimensional data creating a digital signature for the patient while enabling data quality, integrity, and traceability acquired in a high-trust environment.
-
65 minute(s)
Radiologic Analysis of COVID-19 Infection
Related Resources
Related Resources
University Hospital Tübingen: Study shows prediction power of clinical and CT imaging biomarkers
A recent retrospective study [1] conducted by researchers at University Hospital Tuebingen focused on identifying imaging and clinical predictors of…
Royal Marsden London: Study shows prediction power of CT-based 2D and 3D texture analysis for liver metastases
In a retrospective study [1], a team from Royal Marsden in London and Sutton explored changes of CT texture analysis metrics in unresectable liver…
University Hospital Ulm: Pilot study shows discriminatory power of MRI-based 3d texture analysis for bone lesions
Distinguishing between enchondroma, a benign tumor, and low-grade chondrosarcoma, which is a low-aggressivity malignancy, is a frequent challenge, as…